Your browser doesn't support javascript.
loading
[Prospect of novel therapies in immune-mediated neuropathies].
Kuwahara, Motoi.
Affiliation
  • Kuwahara M; Department of Neurology, Kindai University Faculty of Medicine.
Rinsho Shinkeigaku ; 64(1): 1-7, 2024 Jan 20.
Article de Ja | MEDLINE | ID: mdl-38072443
The efficacy of immunotherapies such as steroids, plasmapheresis, and intravenous immunoglobulin have been proven in various immune-mediated neuropathies. However, these treatments sometimes lack the efficacy in a part of patients with the immune-mediated neuropathies. In addition, anti-myelin associated glycoprotein (MAG) neuropathy is usually refractory to the treatments. Recently, novel therapies targeting a molecule which are associated with pathogenesis of immune-mediated diseases, have been developed. These molecularly targeted therapies are notable in immune-mediated neuropathies as novel drug candidates. In the present article, current treatments and future prospect of novel therapies in immune-mediated neuropathies will be reviewed.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Syndrome de Guillain-Barré / Polyradiculonévrite inflammatoire démyélinisante chronique Limites: Humans Langue: Ja Journal: Rinsho Shinkeigaku Année: 2024 Type de document: Article Pays de publication: Japon

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Syndrome de Guillain-Barré / Polyradiculonévrite inflammatoire démyélinisante chronique Limites: Humans Langue: Ja Journal: Rinsho Shinkeigaku Année: 2024 Type de document: Article Pays de publication: Japon